Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Apr;104(4):e143-e146.
doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8.

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms

Anna B Halpern  1   2 , Megan Othus  3 , Emily M Huebner  1 , Bart L Scott  1   4 , Paul C Hendrie  2   5 , Mary-Elizabeth M Percival  1   2 , Pamela S Becker  1   2 , Heather A Smith  5 , Vivian G Oehler  1   2 , Johnnie J Orozco  1   2 , Ryan D Cassaday  1   2 , Kelda M Gardner  2 , Tara L Chen  6 , Sarah A Buckley  7 , Kaysey F Orlowski  1 , Asma Anwar  7 , Elihu H Estey  1   2 , Roland B Walter  8   2   9
Affiliations
Clinical Trial

Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms

Anna B Halpern et al. Haematologica. 2019 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Survival estimates for patients treated with CLAG-M at the RP2D and other high-dose cytarabine-containing salvage regimens. Kaplan-Meier estimates of (A) overall survival and (B) relapse-free survival of the 40 patients who received CLAG-M at the RP2D (i.e., using mitoxantrone at a dose of 16mg/m2). (C) Kaplan-Meier estimates of overall survival of TRM score-matched patients who received CLAG-M with mitoxantrone at 10 mg/m2 compared to patients who received CLAG-M with mitoxantrone at 16 mg/m2. (D) Kaplan-Meier estimates of overall survival of patients who received CLAG-M at the R2PD in our study (mitoxantrone at 16 mg/m2) compared to similar patients who received d/MEC and GCLAC at our institution.
See this image and copyright information in PMC

References

    1. Thol F, Schlenk RF, Heuser M, Ganser A. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126(3):319–327. - PubMed
    1. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249–1259. - PMC - PubMed
    1. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235–1248. - PubMed
    1. Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29(33):4417–4423. - PMC - PubMed
    1. Godwin CD, Othus M, Powell MA, Buckley SA, Estey EH, Walter RB. Prediction of early death in adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2016;57(10):2421–2424. - PMC - PubMed

MeSH terms